Investigational drug · Phase 2
Finotonlimab
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Advanced Hepatocellular Carcinoma.
Phase 2Last checked: Nov 19, 2026Latest source record: Jun 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
9
Any phase or sponsor naming "Finotonlimab"
First trial start
2025
Jun 24, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Finotonlimab", any sponsor or status.
Conditions studied
As listed on its trial records.
- Advanced Hepatocellular Carcinoma
Approved drugs for the same conditions: Liver cancer (hepatocellular carcinoma) · Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "Finotonlimab" as an intervention, largest first.
- Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCCPivotal-lookingRecruiting
Ji DongmeiAcademic, hospital or other
NCT07509099 · 316 participants (planned) · Start Sep 15, 2026 · Primary completion Sep 30, 2031
Drug: cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy; PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy · For: Squamous Cell Carcinoma of Head and Neck
Sites: Shanghai, China · 2 sites in all
- Perioperative Finotonlimab Plus Chemotherapy in Untreated Stage II HNSCCPivotal-lookingNot yet recruiting
Yanjie Zhang, MDAcademic, hospital or other
NCT07751276 · 142 participants (planned) · Start Aug 1, 2026 · Primary completion Dec 31, 2029
Drug: Neoadjuvant Finotonlimab Plus Chemotherapy; Postoperative Finotonlimab Maintenance · For: Head and Neck Squamous Cell Carcinoma HNSCC
- A Multicenter, Prospective Study of Perioperative Finotonlimab Combined With Bevacizumab in Resectable Hepatocellular Carcinoma Patients With High-Risk Factors for RecurrenceActive, not recruiting
Tongji HospitalAcademic, hospital or other
NCT07009470 · 130 participants (planned) · Start Feb 10, 2025 · Primary completion Apr 28, 2028
Drug: Finotonlimab (an anti-PD-1 monoclonal antibody) and Anbeizhu (a bevacizumab biosimilar) · For: HCC
Sites: Wuhan, China
- Neoadjuvant Chemotherapy Combined With Finotonlimab in the Treatment of Locally Advanced Hypopharyngeal CarcinomaPivotal-lookingRecruiting
Eye & ENT Hospital of Fudan UniversityAcademic, hospital or other
NCT07248956 · 116 participants (planned) · Start Dec 22, 2025 · Primary completion Nov 30, 2027
Drug: Finolizumab; Albumin-Bound Paclitaxel /nab-Paclitaxel and 1 more · For: Hypopharyngeal Carcinoma
Sites: Harbin, China; Jinan, China; Beijing, China · 7 sites in all
Sichuan Baili Pharmaceutical Co., Ltd.Industry
NCT06986785 · 74 participants (planned) · Start Jun 24, 2025 · Primary completion May 2027
Drug: BL-B01D1; Lenvatinib and 2 more · For: Advanced Hepatocellular Carcinoma
Sites: Shanghai, China
- BRIDGE Study: Neoadjuvant Finotonlimab, Cetuximab, and Docetaxel in Resectable Recurrent HNSCC After Immunotherapy ProgressionEnrolling by invitation
Sun Yat-sen UniversityAcademic, hospital or other
NCT07618624 · 42 participants (planned) · Start Apr 20, 2026 · Primary completion Dec 31, 2027
Drug: Finotonlimab; Cetuximab and 2 more · For: Recurrent Head and Neck Squamous Cell Carcinoma; Head and Neck Cancer
Sites: Foshan, China; Guangzhou, China; Shantou, China · 9 sites in all
- Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy Combined With Penpulimab and Fruquintinib for Advanced Colorectal CancerNot yet recruiting
West China HospitalAcademic, hospital or other
NCT07904130 · 32 participants (planned) · Start Oct 9, 2026 · Primary completion Oct 1, 2028
Drug: Immunotherapy; Target Therapy · For: Colo-rectal Cancer
- Neoadjuvant Finotonlimab Plus TP Regimen in Locally Advanced INI-1-Deficient Sinonasal CarcinomaRecruiting
Eye & ENT Hospital of Fudan UniversityAcademic, hospital or other
NCT07927465 · 20 participants (planned) · Start Sep 28, 2026 · Primary completion Dec 31, 2028
Drug: Finotonlimab; Paclitaxel and 1 more · For: SMARCB1-Deficient Sinonasal Carcinoma
Sites: Shanghai, China
- Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal CarcinomaNot yet recruiting
Tang-Du HospitalAcademic, hospital or other
NCT07752394 · 15 participants (planned) · Start Aug 23, 2026 · Primary completion Aug 23, 2031
Drug: Finotonlimab; Nab-paclitaxel and 1 more · For: Head & Neck Cancer
Sites: Xi’an, China
Newest research
PubMed records naming it or its code names, newest first.
- Cost-effectiveness of finotonlimab plus bevacizumab versus sorafenib as first-line therapy in unresectable hepatocellular carcinoma in China.
Xu H, Yu S, Yang Y, et al. · Hum Vaccin Immunother 2026
- Cost-effectiveness analysis of finotonlimab in the treatment of advanced recurrent metastatic head and neck squamous cell carcinoma in China.
Gao Y, Lv N, Diao R · Hum Vaccin Immunother 2026
- Cost-effectiveness analysis of finotonlimab in combination with bevacizumab biosimilar SCT510 as first-line therapy for advanced hepatocellular carcinoma.
He Y, You M · Expert Rev Pharmacoecon Outcomes Res 2026
- Integrating multiple outcomes of first-line immunotherapy-based regimens for advanced hepatocellular carcinoma: A network meta-analysis of phase III trials.
Nie G, Li X, Wang Y, et al. · Crit Rev Oncol Hematol 2026
- Phase Ib Trial of Finotonlimab Combined With SCT200 in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma.
Lin J, Qu S, Yang K, et al. · Cancer Med 2026
- Economic value of finotonlimab plus bevacizumab versus sorafenib for first-line treatment of unresectable hepatocellular carcinoma in China and the United States.
He Y, Jiang Q, Pan X, et al. · Front Public Health 2026
Also in development for Advanced Hepatocellular Carcinoma
- PF-08634404SSGJ-707Phase 312 trials
Pfizer · Non-Small Cell Lung Cancer, Lung Neoplasms, Carcinoma, Non-Small-Cell Lung (NSCLC)
- pegargiminaseADI-PEG 20Phase 33 trials
Polaris Group · Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Advanced Hepatocellular Carcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.